News | September 08, 2008

MicroMed Cardiovascular Purchased, Taken Private by SynCardia CEO, Investors

September 9, 2008 - Ventricular assist device manufacturer MicroMed Cardiovascular Inc. today said it completed all necessary steps and is now a private company.

The final step in the process was a reverse split of its common stock and a repurchase of the fractional shares from the MicroMed shareholders holding smaller positions. At the time of the reverse split, E-Wilson LLC had accumulated 97.5 percent of the outstanding MicroMed shares. MicroMed received confirmation of the reverse split on Aug. 25, 2008, making E-Wilson the single shareholder of MicroMed.

On Feb. 1, 2008, MicroMed entered into a credit agreement with E-Wilson, under which E-Wilson agreed to provide up to $10 million in financing in a series of advances over the next two years, subject to certain conditions.

E-Wilson was formed by Rodger Ford, shareholder and CEO of SynCardia Systems and David Mackstaller, shareholder and vice president of development of SynCardia Systems, as a special purpose entity to own MicroMed shares. While MicroMed and SynCardia have some common shareholders, they are separate and operate as two independent entities.

MicroMed is a pioneer in the accelerating field of mechanical circulatory support and manufactures a small implantable ventricular assist device, the DeBakey VAD, which is intended to increase the cardiac output of a patient with a failing left ventricle. The DeBakey VAD and its related technology were developed in a partnership with NASA. In 1998, the DeBakey VAD became the first device of its kind to be used in humans. It weighs 92 grams and is implanted in the pericardial space.

The DeBakey VAD recently received approval for two upgrades, now approved in Europe with a CE mark and in the U.S. pediatric VAD under a humanitarian device exemption. A bridge to transplant clinical study is underway in the U.S. under an IDE that may eventually lead to a PMA.

The modern DeBakey VAD is the HeartAssist 5. It has a direct flow measurement system intended to provide blood flow data 24/7. The HeartAssist 5 and its earlier DeBakey VAD version have been implanted more than 440 times worldwide.

The HeartAssist 5 Adult VAD is an investigational device, limited by U.S. law to investigational use.

The HeartAssist 5 Pediatric VAD is authorized by federal law for use in providing temporary mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients 5-16 years old who are listed for transplant. The effectiveness of this device for this use has not been demonstrated.

For more information: www.micromedtech.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init